Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stage IIIC or IV Melanoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Stage IIIC or IV Melanoma. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-023526-21 Sponsor Protocol Number: MO25515 Start Date*: 2011-03-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Estudio multicéntrico, abierto, de acceso expandido, de RO5185426 en pacientes con melanoma metastásico An open-label, multicenter expanded access study of RO5185426 in patients with metastatic me...
    Medical condition: Tratamiento de pacientes adultos con melanoma metastásico confirmado histológicamente, portador de la mutación BRAF V600 identificada por medio del test Cobas 4800 para mutaciones BRAF V600, en los...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) SE (Completed) NL (Completed) SI (Completed) GR (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed) SK (Completed) BE (Completed) BG (Completed) NO (Completed) PT (Completed) LV (Completed) FI (Completed) IT (Completed) DK (Completed) EE (Completed) LT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012293-12 Sponsor Protocol Number: NO25026 Start Date*: 2010-01-25
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously untreated Patients with Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF mutation Receiving Vemu...
    Medical condition: First-line therapy for adult patients with histologically confirmed metastatic melanoma (unresectable Stage IIIC or Stage IV) harbouring the V600E positive mutation
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) SE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003640-24 Sponsor Protocol Number: C4221023 Start Date*: 2023-01-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED...
    Medical condition: metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048434 Melanoma malignant aggravated LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027155 Melanoma skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025658 Malignant melanoma of skin of eyelid, including canthus LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025661 Malignant melanoma of skin of other and unspecified parts of face LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025663 Malignant melanoma of skin of trunk, except scrotum LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025660 Malignant melanoma of skin of lower limb, including hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025659 Malignant melanoma of skin of lip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025656 Malignant melanoma of skin of ear and external auditory canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025662 Malignant melanoma of skin of scalp and neck LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025664 Malignant melanoma of skin of upper limb, including shoulder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025653 Malignant melanoma of other specified sites of skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027153 Melanoma of skin, site unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025657 Malignant melanoma of skin of ear and external auricular canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027154 Melanoma of trunk and head LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025666 Malignant melanoma of the anus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056768 Malignant melanoma of skin of lower limb, incl hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056767 Malignant melanoma of skin of eyelid, incl canthus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056769 Malignant melanoma of skin of upper limb, incl shoulder LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056792 Malignant melanoma of skin of trunk, excl scrotum LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077160 Central nervous system melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005569-10 Sponsor Protocol Number: Bottom_2012 Start Date*: 2013-08-19
    Sponsor Name:University Hospital Essen
    Full Title: Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastati...
    Medical condition: Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic), and determined to be BRAF V600 mutation-positive
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003008-11 Sponsor Protocol Number: GO28141 Start Date*: 2013-02-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ...
    Medical condition: BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) AT (Completed) NO (Completed) DE (Completed) BE (Completed) SE (Completed) IT (Completed) NL (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004966-33 Sponsor Protocol Number: UZB-2013-001 Start Date*: 2014-04-30
    Sponsor Name:UZ Brussel
    Full Title: A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanoma
    Medical condition: advanced BRAF V600 mutant melanoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027156 Skin melanomas (excl ocular) HLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005125-30 Sponsor Protocol Number: V1.1 Start Date*: 2008-11-20
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie, Abteilung für Immundermatologie
    Full Title: Rituximab (Mabthera) in metastatic melanoma
    Medical condition: metastatic melanoma patients, clinical stage IIIc/IV ( AJCC2002), disease free
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001558-40 Sponsor Protocol Number: ONCOMPASS-001 Start Date*: 2014-05-08
    Sponsor Name:Uzsoki Hospital
    Full Title: Expanded Access Study of MEK162 in Metastatic or Unresectable NRAS Mutation-positive Melanoma
    Medical condition: Metastatic or Unresectable NRAS Mutation-positive Melanoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005149-40 Sponsor Protocol Number: 202105 Start Date*: 2015-02-03
    Sponsor Name:Laboratoire GlaxoSmithKline
    Full Title: An open label non randomized access study of Trametinib for patients with advanced unresectable (stage IIIc) or distant metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
    Medical condition: Metastatic melanoma with mutation BRAF V 600
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000504-20 Sponsor Protocol Number: VECODUE Start Date*: 2017-10-09
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A phase II trial of vemurafenib plus cobimetinib in patients treated with prior first-line systemic immunotherapy for inoperable locally advanced or metastatic melanoma
    Medical condition: Patients with advanced melanoma who have received one prior immunotherapy systemic regimen for advanced disease, for whom vemurafenib/cobimetinib treatment has been scheduled by the treating physic...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001773-24 Sponsor Protocol Number: GO40558 Start Date*: 2019-12-05
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED M...
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002480-15 Sponsor Protocol Number: M14REP Start Date*: 2014-10-15
    Sponsor Name:The Dutch Working Group on Immunotherapy of Oncology (WIN-O)
    Full Title: A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Metastatic Melanoma; Response Monitoring and Resistance Prediction with Positron E...
    Medical condition: BRAFV600-mutation positive patients with unresectable stage IIIc or IV melanoma.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000874-67 Sponsor Protocol Number: NO25390 Start Date*: 2011-11-04
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of vemurafenib (RO5185426) in pediatric patients with surgically incurable and unresectable Stage ...
    Medical condition: Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) SK (Prematurely Ended) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002615-15 Sponsor Protocol Number: BGBIL006 Start Date*: 2016-12-14
    Sponsor Name:Helse Bergen HF, Haukeland universitetssjukehus
    Full Title: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced no...
    Medical condition: Advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003038-98 Sponsor Protocol Number: BeyPro2 Start Date*: 2017-11-23
    Sponsor Name:INTERGRUPPO MELANOMA ITALIANO
    Full Title: An evaluation of the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positi...
    Medical condition: BRAFV600 mutation-positive metastatic melanoma in focal progression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005277-36 Sponsor Protocol Number: GEM-01-15 Start Date*: 2015-02-19
    Sponsor Name:Grupo Español Multidisciplicinar de Melanoma (GEM)
    Full Title: A randomized Phase II study of vemurafenib plus cobimetinib continuous versus intermittent, in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metas...
    Medical condition: BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006140-20 Sponsor Protocol Number: 005/05 Start Date*: 2009-06-01
    Sponsor Name:BioVex Inc
    Full Title: A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEX GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage ...
    Medical condition: Unresectable Stage IIIb, IIIc and IV Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002059-40 Sponsor Protocol Number: ECT-LANS-IL2 Start Date*: 2012-06-28
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients
    Medical condition: Metastatic Cutaneous and Subcutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002827-15 Sponsor Protocol Number: A3671009 Start Date*: 2006-01-19
    Sponsor Name:Pfizer Ltd. [...]
    1. Pfizer Ltd.
    2.
    Full Title: Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) BE (Completed) SE (Completed) GR (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005406-54 Sponsor Protocol Number: M14TIL Start Date*: 2014-05-09
    Sponsor Name:Antoni van Leeuwenhoek ziekenhuis
    Full Title: Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab...
    Medical condition: Patients with unresectable and metastatic (stage IIIc and stage IV) melanoma will be randomized to either treatment arm A (ipilimumab) or treatment arm B (TIL) after metastasectomy and feasibility ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:51:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA